These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 1855324

  • 21. [Effect of ligustrazine on proliferative glomerulonephritis].
    Tang X.
    Zhong Yao Cai; 2003 Aug; 26(8):611-2. PubMed ID: 14649206
    [Abstract] [Full Text] [Related]

  • 22. [Glomerulonephritis therapy. Immunosuppression or coagulation inhibitors - a comparison].
    Schmitt E, Sinn W, Lakner V, Ratner M, Tomilina N.
    Z Gesamte Inn Med; 1980 Aug 01; 35(15):Suppl 45-8. PubMed ID: 7467565
    [Abstract] [Full Text] [Related]

  • 23. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis.
    Chan MK, Kwan SY, Chan KW, Yeung CK.
    Am J Kidney Dis; 1987 May 01; 9(5):417-21. PubMed ID: 3555016
    [Abstract] [Full Text] [Related]

  • 24. IgA nephropathy: a long-term progressive study.
    Orłowski T, Górski A, Rancewicz Z, Morzycka-Michalik M, Smogorzewski M, Małdyk M, Lao M, Szczesny-Nowicka B.
    Miner Electrolyte Metab; 1990 May 01; 16(1):54-6. PubMed ID: 2325593
    [Abstract] [Full Text] [Related]

  • 25. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW, Fluck RJ, Lambie SH.
    Clin Nephrol; 2001 Sep 01; 56(3):193-8. PubMed ID: 11597033
    [Abstract] [Full Text] [Related]

  • 26. Concomitant therapy with prednisolone and cyclophosphamide in 17 cases with IgA nephropathy.
    Katsumata Y, Hasegawa K, Hoshino K.
    Nihon Jinzo Gakkai Shi; 1985 Mar 01; 27(3):295-302. PubMed ID: 4021193
    [No Abstract] [Full Text] [Related]

  • 27. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
    Tsuruya K, Harada A, Hirakata H, Mitsuiki K, Johko T, Kondoh H, Takechi S, Fujishima M.
    Clin Nephrol; 2000 Jan 01; 53(1):1-9. PubMed ID: 10661476
    [Abstract] [Full Text] [Related]

  • 28. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F, Vecchio LD, Pozzi C.
    Nat Clin Pract Nephrol; 2006 Jan 01; 2(1):24-31. PubMed ID: 16932386
    [Abstract] [Full Text] [Related]

  • 29. Effect of combined immunosuppressive anticoagulant and antiplatelet therapy of the course of chronic mesangial-proliferative glomerulonephritis.
    Matousovic K, Matl I, Zabka J, Zástava V, Rossmann P, Prát V.
    Czech Med; 1985 Jan 01; 8(3):151-7. PubMed ID: 3932033
    [Abstract] [Full Text] [Related]

  • 30. Are anticoagulants beneficial in the treatment of rapidly progressive glomerulonephritis?
    Cameron JS.
    Proc Eur Dial Transplant Assoc; 1973 Jan 01; 10(0):57-90. PubMed ID: 4606240
    [No Abstract] [Full Text] [Related]

  • 31. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
    Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, Suzuki H.
    Clin Exp Nephrol; 2003 Mar 01; 7(1):48-51. PubMed ID: 14586743
    [Abstract] [Full Text] [Related]

  • 32. Dipyridamole (persantin) and warfarin in the treatment of glomerulonephritis.
    First MR, Goldberg B, Abrahams C.
    S Afr Med J; 1972 Jun 17; 46(25):848-9. PubMed ID: 5076072
    [No Abstract] [Full Text] [Related]

  • 33. Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies.
    Woo KT, Chiang GS, Yap HK, Lim CH.
    Ann Acad Med Singap; 1988 Apr 17; 17(2):226-31. PubMed ID: 3408224
    [Abstract] [Full Text] [Related]

  • 34. The treatment of glomerulonephritis.
    Kincaid-Smith P.
    Aust N Z J Med; 1980 Jun 17; 10(3):340-5. PubMed ID: 6931575
    [No Abstract] [Full Text] [Related]

  • 35. Effect of dipyridamole treatment on proteinuria in pediatric renal disease.
    Ueda N, Kawaguchi S, Niinomi Y, Nonoda T, Ohnishi M, Ito S, Yasaki T.
    Nephron; 1986 Jun 17; 44(3):174-9. PubMed ID: 3785481
    [Abstract] [Full Text] [Related]

  • 36. [Treatment of IgA nephropathy].
    Matousovic K, Mestecky J, Tomana M, Novak J.
    Vnitr Lek; 2008 Mar 17; 54(3):239-44. PubMed ID: 18522291
    [Abstract] [Full Text] [Related]

  • 37. Long-term effects of intensive therapy combined with tonsillectomy in patients with IgA nephropathy.
    Hotta O, Taguma Y, Yoshizawa N, Oda T, Nishiyama J, Yusa N, Chiba S, Horigome I, Sudo K, Tomioka S.
    Acta Otolaryngol Suppl; 1996 Mar 17; 523():165-8. PubMed ID: 9082770
    [Abstract] [Full Text] [Related]

  • 38. Decrease of mesangial matrix after immunosuppressive therapy in children with reversible membranoproliferative glomerulonephritis type I.
    Inaba S, Tanizawa T, Takahashi T, Ishihara S, Arai M, Sakai Y, Kurose KK, Matsukura H, Okada T.
    Clin Nephrol; 1996 Apr 17; 45(4):217-25. PubMed ID: 8861795
    [Abstract] [Full Text] [Related]

  • 39. Treatment of vasculitic IgA nephropathy.
    Harper L, Ferreira MA, Howie AJ, Savage CO, Richards NT, Michael J, Adu D.
    J Nephrol; 2000 Apr 17; 13(5):360-6. PubMed ID: 11063140
    [Abstract] [Full Text] [Related]

  • 40. Severe fibrin and crescent glomerulonephritis: clinical and morphological aspects of 33 patients.
    Mathew TH, Kincaid-Smith P.
    Perspect Nephrol Hypertens; 1973 Apr 17; 1 Pt 2(0):727-34. PubMed ID: 4803314
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.